Amplia Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATX.AX research report →
Price Chart
About the company
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.
- CEO
- Chris Burns
- IPO
- 2013
- Employees
- 8
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on ATX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $77.00M
- P/E
- -8.98
- PEG
- -0.37
- P/S
- 0.00
- P/B
- 1.95
- EV/EBITDA
- -3.84
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -18.71%
- ROIC
- -20.41%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-92,141-102.6%
- Op Income
- $-13,180,112
- Net Income
- $-7,707,152-17.3%
- EPS
- $-0.02+23.4%
- OCF Growth
- -26.8%
- FCF Growth
- -27.3%
- 52W High
- $0.28
- 52W Low
- $0.10
- 50D MA
- $0.14
- 200D MA
- $0.14
- Beta
- -0.40
- RSI (14)
- 54
- Avg Volume
- 1.23M
No earnings-call transcripts are available for ATX.AX yet.
- Free Float
- 80.7%
- Shares Outstanding
- 513.31M
- Float Shares
- 414.17M
of shares held by institutions
1 13F filers
Our ATX.AX coverage
Recent articles, reports, and earnings notes.
No research on ATX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATX.AX report →Amplia Therapeutics partners with Lilly on lung cancer combination trial
proactiveinvestors.com · Aug 4
Altona Rare Earths shares jump 11% as gallium results exceed expectations at Mozambique project
proactiveinvestors.com · Mar 24
Amplia flags key ACCENT milestone as 5 complete responses sharpen narmafotinib case in pancreatic cancer
proactiveinvestors.com · Mar 23
X‑Energy files to go public on the Nasdaq, eyes $300M raise
proactiveinvestors.com · Mar 23
Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
globenewswire.com · Dec 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.